Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals Stock Forecast

Stock Price Forecast

The 26 analysts that cover Alnylam Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $474.42, which forecasts a 39.90% increase in the stock price over the next year. The lowest target is $351 and the highest is $583.

Price Target: $474.42 (+39.90%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$351	$474.42	$489	$583
Change	+3.51%	+39.90%	+44.20%	+71.92%

Analyst Ratings

The average analyst rating for Alnylam Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25	Jan '26
Strong Buy	13	14	13	13	13	12
Buy	10	11	11	10	10	10
Hold	4	4	3	4	5	5
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	27	29	27	27	28	27

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Michael Ulz Morgan Stanley	Morgan Stanley	Hold Maintains $495 → $408	Hold	Maintains	$495 → $408	+20.31%	Jan 30, 2026
Tazeen Ahmad B of A Securities	B of A Securities	Strong Buy Maintains $529 → $462	Strong Buy	Maintains	$529 → $462	+36.24%	Jan 30, 2026
Patrick R. Trucchio HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $570 → $510	Strong Buy	Maintains	$570 → $510	+50.39%	Jan 30, 2026
Eliana Merle Barclays	Barclays	Buy Initiates $527	Buy	Initiates	$527	+55.41%	Jan 28, 2026
Luca Issi RBC Capital	RBC Capital	Buy Maintains $500 → $465	Buy	Maintains	$500 → $465	+37.12%	Jan 20, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

3.83B

Increased by 70.44%

from 2.25B

Revenue Next Year

5.53B

Increased by 44.39%

from 3.83B

EPS This Year

2.38

from -2.18

EPS Next Year

7.16

Increased by 200.61%

from 2.38

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	492.85M	844.29M	1.04B	1.83B	2.25B	3.83B	5.53B
Revenue Growth	124.28%	71.31%	22.88%	76.24%	22.97%	70.44%	44.39%
EPS	-7.46	-7.20	-9.30	-3.52	-2.18	2.38	7.16
EPS Growth	-	-	-	-	-	-	200.61%
Forward PE	-	-	-	-	-	142.33	47.35
No. Analysts	-	-	-	-	-	31	31

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	4.4B	6.4B
Avg	3.8B	5.5B
Low	3.2B	4.6B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	97.4%	67.0%
Avg	70.4%	44.4%
Low	44.5%	19.9%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	5.51	11.51
Avg	2.38	7.16
Low	1.06	2.13

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	383.0%
Avg	-	200.6%
Low	-	-10.7%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.